EEG Objectification in Neuropsychiatry

Not Applicable

• Conditions: Personality Disorder; Depression; Neurodegeneration; Alzheimer's Disease; Epilepsy

• Registration Number: NCT01476228
• Lead Sponsor: Hadassah Medical Organization

Brief Summary

The main objective of the study is to evaluate the use of EEG in the management and follow-up of neuropsychiatric disorders. Secondary objectives are therefore better understanding of the pathological activations in neural network during neuropsychiatric disorders, their clinical evolution and response to therapies.

Detailed Description

Patients are having EEG recordings as a routine part of their clinical evaluation and diagnosis. EEG recording is harmless, has no side effects, any radiation or any mechanical or electrical influence. It is of short duration and may be done in the EEG institute or the patient's room.

Study Timeline

• Status Verified: 2011-08
• Study First Submitted: 2011-08-22
• Study Start: 2011-11
• Study First Submitted QC: 2011-11-17
• Last Update Submitted: 2011-11-17
• Study First Posted: 2011-11-22
• Last Update Posted: 2011-11-22
• Primary Completion: 2013-11
• Study Completion: 2015-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• diagnosis of the investigated neuropsychiatric disease

Exclusion Criteria

• Other co-existing neuropsychiatric conditions
• Refusal to participate in the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
percentage of fitting (0-100%) of EEG pattern to a previously identified electrophysiological "key"	1 year	The study will decode an EEG-based "key" (or electrophysiological pattern) for specific effect (such as the use of anti-epileptic agent or a certain condition) by comparing EEG before and after the use of this agent. For each patient the statistical fitting of the recorded EEG to the key will be evaluated by percentage (0-100%), describing fitting of the individual patient's EEG to the identified key.

Trial Locations

Locations (1)

HMO; 🇮🇱 Jerusalem, Israel